Stay updated on CAB-AXL-ADC in Sarcoma Clinical Trial

Sign up to get notified when there's something new on the CAB-AXL-ADC in Sarcoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CAB-AXL-ADC in Sarcoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the safety and efficacy assessment of mecbotamab vedotin (BA3011) in patients with solid tumors, particularly in the context of a Phase 1/2 study for advanced sarcomas.
    Difference
    0.1%
    Check dated 2024-06-06T14:24:52.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying requirements such as measurable disease, age, and adequate organ function, among others. Previously, no information was provided regarding participation criteria.
    Difference
    10%
    Check dated 2024-05-22T20:55:55.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:37:07.000Z thumbnail image

Stay in the know with updates to CAB-AXL-ADC in Sarcoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CAB-AXL-ADC in Sarcoma Clinical Trial page.